To compare the efficacies of cefepime and ceftazidime as empiric therapy during the management of fever in cancer patients with chemotherapy-induced neutropenia.
METHODS:
A prospective, double-blind, randomized study of cefepime 2 g every eight hours and ceftazidime 2 g every eight hours was performed in 276 adult neutropenic (absolute neutrophil count <500/mm3) cancer patients with fever.
RESULTS:
Median duration of neutropenia was five days. Sixty-one percent (n = 188) of the patients were evaluable. Treatment was successful in 57% (58/101) of cefepime-treated patients and 60% (52/87) of ceftazidime-treated patients (95% CI −18 to 12; p = 0.77). Bacteremic clearance occurred in 71% (12/17) of cefepime-treated patients and 40% (6/15) of ceftazidime-treated patients (p = 0.3). Both drugs were well tolerated.
CONCLUSIONS:
Cefepime appears to be as effective as ceftazidime in the initial treatment of febrile episodes in adult cancer patients with chemotherapy-associated neutropenia of modest duration.
SchimpffSCSaterleeWYoungVMSerpickA. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med1971;284:1061–5.
2.
SchimpffSCScottDAWadeJC. Infections in cancer patients: Some controversial issues. Support Care Cancer1994;2:94–104.
3.
PizzoPAHathornJWHiemenzJWBrowneMCommersJCottonDA randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med1986;315:552–8.
4.
RamphalR. Is monotherapy for febrile neutropenia still a viable alternative?Clin Infect Dis1999;1:508–14.
5.
RamphalRGucalpRRotsteinCCiminoMOblonD. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med1996;100(suppl 6A):83S–9S.
6.
YamamuraDGucalpRCarlislePCiminoMRobertsJRotsteinC. Open randomized study of cefepime versus piperacillin—gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother1997;41:1704–8.
7.
JohanssonPJSternbyEUrsingB. Septicemia in granulocytopenic patients: A shift in bacterial etiology. Scand J Infect Dis1992;24:357–60.
8.
RolstonKVIBerkeyPBodeyGPAnaissieEJKhardoriNMJoshiJHA comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med1992;152:283–91.
9.
BurwenDRBanerjeeSNGaynesRP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System. J Infect Dis1994;170:1622–5.
10.
AlcaideFLiñaresJPallaresJCarratalaJBenitezMAGudiolFIn vitro activities of 22 β -lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother1995;39:2243–7.
11.
JohnsonCCLivorneseLGoldMJPitsakisPGTaylorSLevisonME. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula. J Antimicrob Chemother1995;35:765–73.
12.
JonesRNPfallerMADoernGVErwinMEHollisRJ. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: A 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group. Diagn Microbiol Infect Dis1998;30:215–28.
13.
SaderHSMimicaIRossiFZoccoliCMontelliACSampaioJLEvaluation of the in vitro activity of cefepime compared to other broad-spectrum cephalosporins against clinical isolates from eighteen Brazilian hospitals by using the E test. Diagn Microbiol Infect Dis1997;28:87–92.
14.
HughesWTArmstrongDBodeyGPBrownAEEdwardsJEFeldR1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis1997;25:551–73.
15.
National Committee for Clinical Laboratory Standards.Performance standards for antimicrobial susceptibility testing. 8th Informational supplement. Wayne, PA: NCCLS, 1998;NCCLS document M-100-S58.
16.
Immunocompromised Host Society. Design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis1990;161:397–401.
17.
EggimannPGlauserMPAounMMeunierFCalandraT. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother1993;32(suppl):S151–63.
18.
CordonierCHerbrechtRPicoJLGardembasMDelmarADelainM, for the Cefepime Study Group. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: A comparative study. Clin Infect Dis1997;24:41–51.
19.
BironPFuhrmannCCureHViensPLefebvreDThyssACefepime versus imipenem—cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. J Antimicrob Ther1998;42:511–8.
20.
RamphalRBolgerMOblonDJSheretzRJMaloneJDRandKHVancomycin is not an essential component of the initial empiric treatment for febrile neutropenic patients receiving ceftazidime: A randomized prospective study. Antimicrob Agents Chemother1992;36:1062–7.
21.
NovákováIRODonnellyJPDePauwBE. Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteria in febrile granulocytopenic patients. Antimicrob Agents Chemother1991;35:672–8.
22.
The EORTC International Antimicrobial Therapy Comparative Group and National Cancer Institute of Canada. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis1991;163:951–8.
23.
NovákováIRODonnellyJPVerhagenCSDePauwBE. Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients. J Antimicrob Chemother1990;25:985–93.
24.
Centers for Disease Control and Prevention.Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol1995;16:106–13.
25.
DePauwBEDeresinskiSCFeldRLane-AllmanEFDonnellyJP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: A multicenter randomized trial. Ann Intern Med1994;120:834–44.
26.
Drug topics redbook. Montvale, NJ: Medico Economics Data, January 1999.
